Larkberget

Larkberget ROCE

The Return on Capital Employed (ROCE) of Larkberget (LARK.ST) as of Oct 28, 2026 is -23.38 %. In the previous year, Return on Capital Employed (ROCE) was -65.97 % — a change of -64.55% (higher).

ROCE

-23.38 %

YoY

-64.55%

Last updated:

In 2025, Larkberget's return on capital employed (ROCE) was -23.38 %, a -64.55% increase from the -65.97 % ROCE in the previous year.

The Larkberget ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-64.44 SEK
Jan 1, 2019
-87.13 SEK
Jan 1, 2020
-39.42 SEK
Jan 1, 2021
13.25 SEK
Jan 1, 2022
-4.57 SEK
Jan 1, 2023
-33.15 SEK
Jan 1, 2024
-65.97 SEK
Jan 1, 2025
-23.38 SEK
The Larkberget ROCE history
YEARROCEYoY
-23.38 %-64.55%
-65.97 %+99.02%
-33.15 %+625.80%
-4.57 %-134.48%
13.25 %-133.60%
-39.42 %-54.76%
-87.13 %+35.22%
-64.44 %-53.16%
-137.56 %-35.24%
-212.43 %+248.69%
-60.92 %+259.15%
-16.96 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Larkberget Stock analysis

What does Larkberget do? CombiGene AB specializes in developing treatments for neurological disorders using gene therapy vectors. The company's platform delivers combinations of transgenes encoding neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors. CombiGene focuses on an epilepsy treatment utilizing an adeno-associated virus (AAV) vector carrying transgenes for NPY and its Y2 receptor. The firm targets neurological and psychiatric diseases in humans and animals through its gene therapy approach. CombiGene AB's products are developed for the treatment of epilepsy and other neurological conditions. The company's platform is designed to deliver multiple therapeutic elements simultaneously via gene therapy vectors. The firm's focus on AAV vectors carrying specific transgenes reflects its strategy to address complex neurological disorders with targeted gene-based therapies. The company's target segments include patients with neurological and psychiatric diseases requiring innovative treatment options. CombiGene AB's development pipeline centers on epilepsy treatment using NPY and Y2 receptor transgenes. The firm's approach involves creating therapies that combine multiple biological components to address disease mechanisms more effectively. Larkberget is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Larkberget's Return on Capital Employed (ROCE)

Larkberget's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Larkberget's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Larkberget's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Larkberget’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Larkberget stock

Return on Capital Employed (ROCE) of Larkberget is -23.38 % in 2025.

Return on Capital Employed (ROCE) of Larkberget changed from -65.97 % to -23.38 %, representing a -64.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Larkberget since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Larkberget with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Larkberget

All Key Metrics — Larkberget